CoreCap Advisors’s ADMA Biologics ADMA Stock Holding History

CoreCap Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$285	Hold	34	–	–	﹤0.01%	2954
2026 Q1	$306	Hold	34	–	–	﹤0.01%	2717
2025 Q4	$620	Buy	34 +24	+240%	+$404	﹤0.01%	2673
2025 Q3	$147	Buy	+10	New	+$171	﹤0.01%	2699
2025 Q2	–	Sell	-7	Closed	-$139	–	2765
2025 Q1	$139	Sell	7 -39,908	-100%	-$690K	﹤0.01%	3033
2024 Q4	$685K	Buy	39,915 +4,813	+14%	+$90.5K	0.03%	405
2024 Q3	$702K	Buy	+35,102	New	+$546K	0.03%	390

Other funds holding ADMA

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

KPP

Kings Path Partners Sugar Land, Texas $376M AUM 19% 1-Year Est. Return

CoreCap Advisors's ADMA Position: Q2 2026 in Review

CoreCap Advisors held its ADMA Biologics (ADMA) position steady in Q2 2026 at 34 shares worth $285. The position accounts for ﹤0.01% of the portfolio, ranked #2954.

CoreCap Advisors first reported a position in ADMA in Q3 2024 and has held it in 7 quarters since. The position peaked at $702K in Q3 2024. 33 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

CoreCap Advisors held 34 shares of ADMA Biologics worth $285 as of Q2 2026.
CoreCap Advisors left its ADMA Biologics share count unchanged in Q2 2026.
ADMA Biologics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2954 holding.
CoreCap Advisors first reported a position in ADMA Biologics in Q3 2024 and has held it in 7 quarters since.
CoreCap Advisors's ADMA Biologics position peaked at $702K in Q3 2024.
33 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.